To determine whether ESRP2 has a similar prognostic effect compared to ESRP1 and whether a combined analysis of multiple ESRP family members would result in even better prognostic information, immunohistochemical analysis was performed on a tissue microarray (TMA) containing more than 17,000 prostate cancers with long-term follow-up data. The gene discussed is ESRP1; the disease is prostate cancer.